Physician profile
Roy C Fu
NPI 1972686632
$5,003.20
in general payments reported to CMS, 2019-2025
28 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $553 · 2021: $716 · 2022: $903 · 2023: $1,139 · 2024: $788 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $927.53 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $673.64 | 2019-2024 | Dificid, Verquvo |
| Novartis Pharmaceuticals Corporation | $579.97 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $441.54 | 2020-2023 | Camzyos, Eliquis |
| Shionogi INC | $427.57 | 2020-2024 | Fetroja |
| Pfizer INC. | $324.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.56 | 2021-2025 | Jardiance, Spiriva Respimat, Cyltezo |
| Abiomed | $320.33 | 2023-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $215.82 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.93 | 2023 | Xifaxan |
| Covidien LP | $91.59 | 2019 | |
| Verona Pharma, INC. | $72.14 | 2025 | Ohtuvayre |
| Allergan, INC. | $65.41 | 2019 | |
| Csl Behring | $55.56 | 2019-2020 | |
| Medtronic Vascular, INC. | $38.64 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.03 | 2023 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.13 | 2025 | Lifevest |
| Gilead Sciences, INC. | $28.47 | 2025 | |
| Celgene Corporation | $26.95 | 2022 | |
| Kci USA, INC. | $26.27 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $24.69 | 2019 | |
| Sobi, INC | $24.67 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.68 | 2021 | |
| Aimmune Therapeutics, INC. | $23.01 | 2024 | |
| Cytovale, INC. | $21.26 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.26 | 2020 | |
| Abbvie INC. | $18.87 | 2022 | |
| Ucb, INC. | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.